drugset / Trial / NCT06754501
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
Phase 2
Active not recruiting
4 enrolled
M.D. Anderson Cancer Center
Genentech, Inc. · collabStrategic Alliance · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied
Timeline
- Start
- 2025-04-11
- Primary completion
- 2027-07-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | — | Intravenous |